# Jennerex, Inc.: Form D filings

Jennerex, Inc., a biotechnology company in San Francisco, CA, filed 3 Form D notices with the SEC in 2011. The latest, on October 13, 2011, reports $1.8 million sold of a $1.8 million offering to 1 investor.

Find out what Jennerex, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20Jennerex%2C%20Inc.%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=Jennerex%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fjennerex-inc-1525143)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20Jennerex%2C%20Inc.%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=Jennerex%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fjennerex-inc-1525143)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in California](https://specstream.ai/data/form-d/state/california): 5,891 rows, by operating companies, filed since November 1, 2024, $138.91, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/california
- [Form D filings in Biotechnology](https://specstream.ai/data/form-d/industry/biotechnology): 1,568 rows, by operating companies, filed since November 1, 2024, $78.40, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/biotechnology

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 450 SANSOME STREET, 16TH FLOOR, San Francisco, CA, 94111
- Phone: (415) 281-8886
- Industry: Biotechnology
- Entity type: Corporation
- Incorporated in: Delaware
- Revenue range: Decline to Disclose
- Exemptions claimed: Rule 506
- SEC identifier (CIK): 1525143

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Oct 13, 2011 | New notice | $1,750,006 | $1,750,006 | $0 | 1 | Sep 9, 2011 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1525143/000152514311000004/0001525143-11-000004-index.htm) |
| Aug 18, 2011 | Amendment | $10,000,000 | $8,601,363 | $1,398,637 | 74 | Jul 6, 2011 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1525143/000152514311000002/0001525143-11-000002-index.htm) |
| Jul 11, 2011 | New notice | $10,000,000 | $3,630,146 | $6,369,854 | 53 | Jul 6, 2011 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1525143/000152514311000001/0001525143-11-000001-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Dr. Terry D Hermiston | Director |  |
| Dr. John C Bell | Director |  |
| Ken R Newport | Executive Officer, Director |  |
| Daniel K Spiegelman | Director |  |
| Hoyoung D Huh | Director |  |
| David Kirn | Executive Officer, Director |  |
| Brennan R Mulcahy | Director |  |
| Dr. Hartley K Stern | Director |  |
| Gregory Schafer | Executive Officer |  |
| Lara Longpre | Executive Officer |  |
| Peter D Charbonneau | Director |  |

## Other biotechnology companies in California that filed recently

- [CARI Health, Inc.](https://specstream.ai/data/form-d/company/cari-health-inc-1930994) $280,000 · Nov 6, 2026
- [Ausel, Inc.](https://specstream.ai/data/form-d/company/ausel-inc-2124022) $120,000 · Nov 4, 2026
- [Trellis Bioscience, Inc.](https://specstream.ai/data/form-d/company/trellis-bioscience-inc-1162015) $9.1 million · Oct 29, 2026
- [BigHat Biosciences, Inc.](https://specstream.ai/data/form-d/company/bighat-biosciences-inc-1797256) $75.1 million · Oct 26, 2026
- [Theravie Pharma, Inc.](https://specstream.ai/data/form-d/company/theravie-pharma-inc-2160768) $750,000 · Oct 19, 2026
- [Adela, Inc.](https://specstream.ai/data/form-d/company/adela-inc-1852167) $12 million · Oct 19, 2026
- [Estuary Biotherapeutics, Inc.](https://specstream.ai/data/form-d/company/estuary-biotherapeutics-inc-2138862) $40.7 million · Oct 16, 2026
- [Renue Life Sciences, Inc.](https://specstream.ai/data/form-d/company/renue-life-sciences-inc-2158207) $250,000 · Oct 14, 2026
- [Tempest Therapeutics, Inc.](https://specstream.ai/data/form-d/company/tempest-therapeutics-inc-1544227) $7.5 million · Oct 14, 2026
- [Lionheart Health, Inc.](https://specstream.ai/data/form-d/company/lionheart-health-inc-2156758) $387,500 · Oct 7, 2026
- [Rakuten Medical, Inc.](https://specstream.ai/data/form-d/company/rakuten-medical-inc-1595215) $9 million · Oct 6, 2026
- [Zonaliz, Inc.](https://specstream.ai/data/form-d/company/zonaliz-inc-2157556) $2.5 million · Oct 5, 2026
- [Altay Therapeutics, Inc.](https://specstream.ai/data/form-d/company/altay-therapeutics-inc-2157551) $15.7 million · Oct 2, 2026
- [Sialia Therapeutics, Inc.](https://specstream.ai/data/form-d/company/sialia-therapeutics-inc-2156754) $1.5 million · Sep 29, 2026
- [Vetmab Biosciences, Inc.](https://specstream.ai/data/form-d/company/vetmab-biosciences-inc-1932050) $11.4 million · Sep 29, 2026

[Every Form D from the week of Oct 10, 2011](https://specstream.ai/data/form-d/week/2011-10-10) · [All recent filings in California](https://specstream.ai/data/form-d/state/california) · [All recent Biotechnology filings](https://specstream.ai/data/form-d/industry/biotechnology)

Read from SEC EDGAR. Amount sold is what Jennerex, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).